Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 280

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells

Open access
Codarri Deak, Laura, Nicolini, Valeria, Hashimoto, Masao, Karagianni, Maria, Schwalie, Petra C., Lauener, Laura, Varypataki, Eleni Maria, Richard, Marine, Bommer, Esther, Sam, Johannes, Joller, Stefanie, Perro, Mario, Cremasco, Floriana, Kunz, Leo, Yanguez, Emilio, Hüsser, Tamara, Schlenker, Ramona, Mariani, Marisa, Tosevski, Vinko, Herter, Sylvia, Bacac, Marina, Waldhauer, Inja, Colombetti, Sara, Gueripel, Xavier, Wullschleger, Stephan, Tichet, Melanie, Hanahan, Douglas, Kissick, Haydn T., Leclair, Stephane, Freimoser-Grundschober, Anne, Seeber, Stefan, Teichgräber, Volker, Ahmed, Rafi, Klein, Christian, Umaña, Pablo·2022·Nature

Abstract

Expansion and differentiation of antigen-experienced PD-1 + TCF-1 + stem-like CD8 + T cells into effector cells is critical for the success of immunotherapies based on PD-1 blockade 1–4 . Hashimoto et al. have shown that, in chronic infections, administration of the cytokine interleukin (IL)-2 triggers an alternative differentiation path of stem-like T cells towards a distinct population of ‘better effector’ CD8 + T cells similar to those generated in an acute infection 5 . IL-2 binding to the IL-2 receptor α-chain (CD25) was essential in triggering this alternative differentiation path and expanding better effectors with distinct transcriptional and epigenetic profiles. However, constitutive expression of CD25 on regulatory T cells and some endothelial cells also contributes to unwanted systemic effects from IL-2 therapy. Therefore, engineered IL-2 receptor β- and γ-chain (IL-2Rβγ)-biased agonists are currently being developed 6–10 . Here we show that IL-2Rβγ-biased agonists are unable to preferentially expand better effector T cells in cancer models and describe PD1-IL2v, a new immunocytokine that overcomes the need for CD25 binding by docking in cis to PD-1. Cis binding of PD1-IL2v to PD-1 and IL-2Rβγ on the same cell recovers the ability to differentiate stem-like CD8 + T cells into better effectors in the absence of CD25 binding in both chronic infection and cancer models and provides superior efficacy. By contrast, PD-1- or PD-L1-blocking antibodies alone, or their combination with clinically relevant doses of non-PD-1-targeted IL2v, cannot expand this unique subset of better effector T cells and instead lead to the accumulation of terminally differentiated, exhausted T cells. These findings provide the basis for the development of a new generation of PD-1 cis -targeted IL-2R agonists with enhanced therapeutic potential for the treatment of cancer and chronic infections.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-022-05192-0

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 68 references

Cited by

See all 280

Metadata

Authors
Codarri Deak, L., Nicolini, V., Hashimoto, M., Karagianni, M., Schwalie, P. C., Lauener, L., Varypataki, E. M., Richard, M., Bommer, E., Sam, J., Joller, S., Perro, M., Cremasco, F., Kunz, L., Yanguez, E., Hüsser, T., Schlenker, R., Mariani, M., Tosevski, V., Herter, S., Bacac, M., Waldhauer, I., Colombetti, S., Gueripel, X., Wullschleger, S., Tichet, M., Hanahan, D., Kissick, H. T., Leclair, S., Freimoser-Grundschober, A., Seeber, S., Teichgräber, V., Ahmed, R., Klein, C., & Umaña, P.
Venue
Nature
Published
2022-09-28
Volume
610
Issue
7930
Pages
161-172
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W4297497772
Cited by
280
References
68
FWCI
17.28
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. https://app.cochat.ai/papers/10.1038/s41586-022-05192-0
The paper
Codarri Deak, L., Nicolini, V., Hashimoto, M., Karagianni, M., Schwalie, P. C., Lauener, L., Varypataki, E. M., Richard, M., Bommer, E., Sam, J., Joller, S., Perro, M., Cremasco, F., Kunz, L., Yanguez, E., Hüsser, T., Schlenker, R., Mariani, M., Tosevski, V., . . . Umaña, P. (2022). PD-1-cis IL-2R agonism yields better effectors from stem-like CD8+ T cells. Nature. https://doi.org/10.1038/s41586-022-05192-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.